FMP

FMP

Enter

SLDB - Solid Biosciences Inc.

Profile of Solid Biosciences Inc.(SLDB), Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United

About

ceo

Mr. Alexander G. Cumbo

sector

Healthcare

industry

Biotechnology

website

https://www.solidbio.com

exchange

NASDAQ

Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

CIK

0001707502

ISIN

US83422E2046

CUSIP

83422E105

Address

141 Portland Street

Phone

617 337 4680

Country

US

Employee

88

IPO Date

Jan 26, 2018

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep